What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-03-26 compared with 2024-04-22 · 49 added, 28 removed, 4 unchanged (95% of the section changed)

FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES

OF EQUITY SECURITIES

for Common Stock

common stock was approved for listing on The NASDAQ Capital Market under the symbol “ MEDS ”, on February 13, 2020.

Prior to that, it traded on the OTCQB Market under the symbol “ TRXD ”.

At present, there is a limited market for our

common stock.

common stock was approved for listing on Nasdaq on February 13, 2020, under the symbol “MEDS”.

On September 24, 2024, in

connection with our acquisition of Scienture, Inc.

(k/n/a Scienture, LLC), we changed our symbol to “SCNX”.

Prior to February

13, 2020, our common stock traded on the OTCQB Market under the symbol “TRXD”.

At present, there is a limited market for

our common stock.

Stock and Preferred Stock Outstanding and Holders of Record

of April 22, 2024, we had 1,406,348 shares of common stock outstanding, held by 52 stockholders of record, not including holders who

hold their shares in street name, and also shares of Series C Preferred Stock issued or outstanding.

we paid a special cash dividend in the first quarter of 2024, we have not historically paid or declared any cash dividends on our common

of March 26, 2025, we had 12,515,019 shares of common stock outstanding, held by 90 stockholders of record, not including holders

who hold their shares in street name as well as 1,575,900 shares of preferred stock issued and outstanding.

we paid a special cash dividend in the first and third quarters of 2024, we have not historically paid or declared any cash dividends

on our common stock.

Any determination to pay dividends in the future will be at the discretion of our board of directors.

Accordingly, investors have

historically relied on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future

gains on their investments.

Accordingly, investors have historically relied on sales of their common stock after price appreciation, which may never occur, as

the only way to realize any future gains on their investments.

Sales of Unregistered Securities

were no sales of unregistered securities during the three months ended December 31, 2023, and from the period from January 1, 2024, to

the filing date of this report, that were not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form

Purchases of Equity Securities

May and December of 2021, the Company’s Board of Directors authorized the repurchase of up to $1 million of the currently outstanding

shares of the Company’s common stock.

Under the stock repurchase program, shares may be repurchased from time to time in the open

market or through negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws.

will be made at management’s discretion at prices management considers to be attractive and in the best interests of both the Company

and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses

for capital, and the Company’s financial performance.

Any open market purchases will be conducted in accordance with the limitations

set forth in Rule 10b-18 of Exchange Act and other applicable legal requirements.

Repurchases may also be made under a Rule 10b5-1 plan.

There was no time frame or expiration date for the repurchase program, and such program was to remain in place until a maximum of $1.0

million of the Company’s common stock had been repurchased or until such program was suspended or discontinued by the Board of

During Fiscal 2023 the Company did not repurchase or any shares of the Company’s

common stock under the repurchase program.

the year ended December 31, 2024, the Company issued 490,698 shares of common stock for services.

The Company relied on the exemption

from registration set forth in Section 4(a)(2) of the Securities Act for this issuance.

July 12, 2024, the Company converted 290 shares of Series C Preferred Stock into 52,158 shares of common stock at the election of the

The Company relied on the exemption from registration set forth in Section 4(a)(2) of the Securities Act for this issuance.

July 25, 2024, as consideration for the acquisition of Scienture LLC, the Company issued to former Scienture, Inc.

stockholders an aggregate

amount of (i) 291,536 shares of the Company’s common stock and (ii) 6,826,713 shares of the Company’s Series X Non-Voting

Convertible Preferred Stock, par value $0.00001 per share (the “Series X Preferred Stock”), each share of which was convertible

into one share of common stock.

On September 20, 2024, all shares of Series X Preferred Stock were converted into a total of 6,826,753

shares of common stock.

Such issuances were made in reliance on the exemptions from registration pursuant to Section 4(a)(2) of the Securities

August 2024, the Company issued a convertible note of $360,000, for which the Company received $314,000 in net proceeds.

The Conversion

Price is the lesser of i) $8.36 or (ii) 85% of the lowest volume-weighted average prices of the preceding five trading days.

matures on August 20, 2025.

In connection with the note, the Company issued 76,923 warrants to purchase common stock.

The warrants have

an exercise price of $9.36 per share, are immediately exercisable and have a term of 5 years.

Such issuances were made in reliance on

the exemptions from registration pursuant to Section 4(a)(2) of the Securities Act.

in August 2024, the Company issued 28,571 shares of common stock pursuant to the exercise of warrants on a cashless basis.

Such issuances

were made in reliance on the exemptions from registration pursuant to Section 4(a)(2) of the Securities Act.

November 22, 2024, the Company issued 55,000 shares of common stock pursuant to a Securities Purchase Agreement dated November 22, 2024.

On November 25, 2024, the Company issued 70,000 shares of common stock pursuant to purchase agreement dated November 25, 2024.

Such issuances

were made in reliance on the exemptions from registration pursuant to Section 4(a)(2) of the Securities Act.

each case, the issuance did not involve a public offering and was made without general solicitation or general advertising, and the recipient

of the shares was an accredited investor.

of Equity Securities by the Issuer and Affiliated Purchasers

Company did not repurchase any shares of common stock during the year ended December 31, 2024.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity